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Abstract: Human prion diseases are a group of rare fatal neurodegenerative diseases with sporadic,
genetic, and acquired forms. They are neuropathologically characterized by pathological prion
protein accumulation, neuronal death, and vacuolation. Classical immunological response has long
been known not to play a major in prion diseases; however, gliosis is known to be a common feature
although variable in extent and poorly described. In this investigation, astrogliosis and activated
microglia in two brain regions were assessed and compared with non-neurologically affected patients
in a representative sample across the spectrum of Creutzfeldt–Jakob disease (CJD) forms and subtypes
in order to analyze the influence of prion strain on pathological processes. In this report, we choose to
focus on features common to all CJD types rather than the diversity among them. Novel pathological
changes in both glial cell types were found to be shared by all CJD types. Microglial activation
correlated to astrogliosis. Spongiosis, but not pathological prion protein deposition, correlated to
both astrogliosis and microgliosis. At the ultrastructural level, astrocytic glial filaments correlated
with pathological changes associated with prion disease. These observations confirm that neuroglia
play a prominent role in the neurodegenerative process of prion diseases, regardless of the causative
prion type.
Keywords: astroglia; microglia; interlaminar astroglia; prion types; cortex; cerebellum
1. Introduction
Creutzfeldt–Jakob disease (CJD) is a group of progressive neurodegenerative patholo-
gies characterized by long incubation periods and an inevitable fatal outcome. The
causative agent is generally held to be the accumulation of misfolded prion protein
(PrPsc) [1]. PrPsc deposition in the brain is a hallmark, but vacuolation, neuronal loss,
and gliosis are all prominent neuropathological features. Although the lack of immune
response was classically associated with prion disease pathogenesis, glial involvement has
been consistently seen [2–8] leading to speculation that glia are crucial players in prion
diseases in accordance with the general neuroinflammatory hypothesis [9–12].
Some authors tend to focus on microglia considering them responsible for the neu-
rodegenerative process characteristic of this group of diseases, in part because microglia are
the main immune cell of the central nervous system (CNS) [13–15]. Their pleomorphism is
widely accepted. Studies of their morphological alterations have suggested a continuum of
changes, from resting to an activated state or as consequence of neuropathological states,
including different morphologies: Ramified, activated, amoeboid, dystrophic, and rod-like
in neurodegenerative disease [16–18]. Evidence indicates that this activated cellular type,
besides contributing to the clearance of damaged cellular material and protein aggregates,
might induce a neuroinflammatory state, which accelerates the development of neurode-
Pathogens 2021, 10, 596. https://doi.org/10.3390/pathogens10050596 https://www.mdpi.com/journal/pathogens
Pathogens 2021, 10, 596 2 of 16
generation [19]. Nevertheless, a definitive view on the role of the activation state of these
glial cells in the neurodegeneration process remains elusive.
In contrast, astroglia were initially considered as building a cellular network in order
to support neurons [20]. However, some studies established close interaction between these
glial cells, microglia, the and brain blood barrier (BBB) [21,22] as well as their involvement
in essential functions for CNS maintenance [20,23]. Additionally, some other studies
provided additional evidence that astrocytes might contribute to the pathogenesis of
neurodegenerative diseases [24–27] have been also published.
Based on this lead role of gliosis as the key regulator of neuroinflammation, some
studies so far have addressed the issue of astrocytic and microglial activation in prion dis-
eases, at the same time establishing a potential neurotoxic [14,15,24,28] or neuroprotective
role [7,29,30] for both cellular types.
On the other hand, the widely known phenotypic heterogeneity of prion diseases
establishes the existence of several CJD types depending on origin (genetic, acquired,
or sporadic) [31]. This variability depends in part on the existence of individual prion
strains. Prion strains are defined as natural infectious isolates characterized by distinctive
clinical and neuropathological features that are faithfully recapitulated in animal models
by transmission studies [32]. The host genotype, in particular the (Met/Val) polymor-
phism at codon 129 of the human prion protein gene PRNP along with the PrPres isoform,
is an also important factor that influences sCJD heterogeneity [33]. Efforts have been
made to establish glial profiles to contribute to prion strain characterization [7,34–36].
Franceschini et al. [37] have recently proposed microgliosis profiling as a valid component
of molecular and histopathological typing. In contrast, our recent study focused on the
preliminary analysis of the astroglial and microglial activation profiles of which brains
from sCJD and fCJD presented some profiles in common [38]. To our knowledge, an
exhaustive study of the possible relationship among glial profiles and findings constituting
neuropathological hallmarks of prion diseases encompassing cases of different CJD types
have not been reported. Although morphological studies are considered to only provide de-
scriptive results by some authors, a link between neuroinflammation and glial phenotypic
changes in neurological diseases constitutes a major current area of research interest.
Therefore, in order to contribute to a clearer understanding of the actual role of host
immune response in prion diseases, we have chosen to characterize the morphological,
distribution, and intensity profiles of astroglial and reactive microglial populations as
agents of the neuroinflammatory process in the different human prion diseases (genetic,
gCJD; iatrogenic, iCJD; variant, vCJD; sporadic, sCJD; and variably protease-sensitive
prionopathy, VPSPr). Each profile is correlated with histopathological findings and PrPsc
accumulation in cerebellum and frontal lobe samples as one of the most and the least
affected encephalic areas, respectively. In contrast to previous studies, our aim consisted
of paying particular attention to features common to all CJD types regarding pathological
changes instead of diversity among them.
2. Results
2.1. Histopathological Findings (Spongiosis and PrPsc Accumulation) and Glial Activation
Spongiform changes were seen in all CJD samples by H/E staining but were absent in
the three control cases (Figure 1). The severity of spongiform change was highly variable
among cases reaching the highest severity in iCJD regardless of the brain region examined
(3.08 ± 0.90 in cerebellum and 2.57 ± 0.93 in frontal cortex; Figure 2). One iCJD MM1 case
showed a spongiosis status compatible with panencephalopathic cases of sCJD.
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Figure 1. Hematoxylin eosin staining (H/E) showing (A) No evidence of spongiosis in a control. (B) Typical spongiform
change associated with CJD. (C) Spongiosis status compatible with panencephalopathic CJD in iCJD MM1.
Figure 2. Comparison of spongiosis, PrPsc deposit, astrogliosis, and reactive microglia scores from the cerebellum and
frontal cortex in different layers and CJD types. Box plots represent median (Me) and interquartile range (IQR); * p < 0.05.
As expected, white matter showed a lower PrPsc accumulation in comparison to grey
matter in both brain regions in all cases examined (0.46 ± 0.72 in cerebellum and 0.33 ± 0.76
in frontal cortex). Consistent with previous reports, a wide variety of different PrPsc
deposits were found, with coalescent and granular patterns of accumulation predominating
in both brain regions. In the frontal cortex, perivascular and pericellular deposits consistent
with glial cell staining was found in 2/3 vCJD samples. The patterns of PrPsc observed
in the different sCJD subtypes was constant to that published previously. For example,
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perivacuolar PrPsc deposits were detected in their frontal cortex, although also to a lesser
degree in two vCJD samples. Additionally, different kinds of protein aggregates were
also highlighted: Kuru plaques were detected in the granular and molecular layer of all
three sCJD MV2 cases and florid plaques in frontal cortex/cerebellum of all three vCJD
cases. Kuru-like plaques were also detected in cerebellum and frontal cortex samples
from iCJD (GMT, MV1) and iCJD (GHT, MV1+2), respectively. Atypical unicentric plaque-
like accumulations were seen in vCJD and also multicentric ones in some sCJD cases.
Microplaques within the molecular layer of the cerebellum were detected in one sample of
VPSPr (Figure 3). PrPsc was not detected in any control samples.
Figure 3. Protein aggregates detected by IHC for PrPsc (12F10 antibody) in samples from different CJD type affected patients.
(A) Kuru-like plaque in the frontal cortex from iCJD (hGH). (B) Kuru plaque in molecular layer from sCJD. (C) Unicentric
plaque with a PrPsc halo atypically surrounding a core in vCJD. (D) Kuru-like plaque in iCJD (hGH). (E) Microplaques in
the molecular layer of cerebellum of VPSPr.
Glial activation significantly increased, reaching the highest values of astrogliosis
(2.96 ± 0.69 and 2.54 ± 0.93) as well as microgliosis (1.92 ± 1.02 and 1.92 ± 0.78) in the
cerebellum and frontal cortex, respectively. Surprisingly, when microglial activation was
assessed with respect to different types, no statistical differences were found. However,
they were found when astrogliosis was studied (p < 0.001).
2.2. Evaluation of Glial Profiles in Different CJD Types
Overall, the degrees of GFAP and activated microglial marker immunoreactivity
correlated with the individual CJD types in both regions of the brain (p < 0.001 in all
cases except for microglia in cerebellum where p = 0.007; Figure 2). The highest GFAP
immunostaining was found in iCJD (3.25 ± 0.87) and sCJD (2.29 ± 1.02) cerebellar and
cortical samples, respectively. Microglial immunoreactivity showed low intensity in all
samples but was especially low in iCJD, vCJD, and VPSPr where they ranged 0.50–0.83 in
cerebellum and 0.29–0.76 in frontal cortex. The highest values were found in cerebellum
from sCJD (1.47 ± 1.21) and frontal cortex from fCJD (1.95 ± 0.80).
Pathogens 2021, 10, 596 5 of 16
2.3. Correlative Analysis between Glial Activation and Neuropathological Lesions
Interestingly, PrPsc deposition was not related to any glial profiles (Table 1). However,
spongiosis correlated to the activation of both astroglial (R = 0.164; p = 0.008) and also
reactive microglial (R = 0.205; p = 0.001) populations. Moreover, the activation of both of
these glial cells highly correlated with each other (R = 0.219; p = 0.000).
Table 1. Correlation among spongiosis, PrPsc accumulation, astrogliosis, and microgliosis in all CJD
types analyzed in the study (Pearson’s correlation).
PrPsc GFAP Microglia
Spongiosis Pearson’s correlation 0.301 ** 0.164 ** 0.205 **
p-value 0.000 0.008 0.001
PrPsc
Pearson’s correlation 1.00 −0.06 0.09
p-value 0.313 0.127
GFAP
Pearson’s correlation 1.00 0.219 **
p-value 0.000
** p < 0.01
2.3.1. Glial Morphological Changes
Similar to that found in our previous studies [38–40], all pathological cerebella shared
two alternative GFAP immunostaining profiles in molecular layer. These consisted of a
mainly radial pattern when astroglial intensity was higher or matching varicose fibers
parallel to the pial surface when it was lower. As a novelty, these profiles were observed
irrespective of strain (Figure 4).
Figure 4. Immunohistochemical patterns observed when astroglial marker (GFAP antibody) was
assessed in sagittal cerebella corresponding to each CJD subtype. Alternative (A–E) radial and
(F–J) horizontal (parallel to the pial surface) profiles were consistently observed in the molecular
layer (Magnification: 400×).
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Concerning the frontal cortex in control samples, mild GFAP immunostaining in the
meninge and in the subpial area mostly coinciding with the supragranular layers (I, II,
and III layer) were found. Additionally, interlaminar astroglia appearing as palisade fibers
with radial morphology were easily identifiable covering I to IV layers. In samples from
CJD affected patients, an increase of GFAP immunostaining in the meninge as well as the
number of interlaminar astrocytic bodies in the I layer and of astrocytes surrounding blood
vessels in deeper layers were found. The most outstanding alterations were focused on
interlaminar glia (Figure 5). These peculiar glia showed several morphological changes that
varied from disorganization or fragmented process to disappearance and/or replacement
by reactive stellate astrocytes, increase of number of terminal masses or disruption. In
the panencephalopathic case, the highest reactive morphology, known as gemistocytic
astrocytes with a spherical pale nucleus, and cellular extensions were identified. The
lack of cytoplasmic prolongation and hyper reactivity was highly marked in white matter.
Additionally, in that case, the interlaminar astroglia showed the thickest process despite
the destruction of typical cytoarchitecture of the frontal cortex.
Figure 5. In comparison with that in healthy control, (A) morphological changes of interlaminar
astroglia in CJD cases are illustrated (GFAP antibody). (B) Replacement by typical stellate astroglial
cells with increase of astrogliosis. (C) Increase of number of terminal masses of interlaminar astroglia.
(D) Increase of diameter of terminal masses. (E) Disruption in I–III frontal cortex. (F) Gemistocytic
phenotype in panencephalopathic CJD (Magnification: 200×, except for (D) 400×).
Astroglial immunostaining always appeared associated with several protein aggre-
gates, not exclusively kuru plaques. Meanwhile, microglial labeling was found to be
associated with protein aggregation or clustered morphology associated with protein
deposit, but only in scarce occasions (Figure 6).
Ramified reactive microglia scattered across all of the examined areas in control
cerebella was found, except for those cerebella that had granular layer degeneration in
which amoeboid appearance was evidenced. In CJD cases, different morphological patterns
were also associated with intensity degree in this brain region: Amoeboid, activated
ramified, rod-like, and dystrophic (Figure 7). Microglia in the Purkinje cell layer remained
in a ramified pattern unlike those in white matter, frequently showing amoeboid shapes.
All healthy control cortex samples showed a sparsely scattered microglial immunostaining
with a ramified morphology (except for some cases where it was dystrophic). In contrast,
in all CJD samples from this encephalic area, a dystrophic pattern was consistently found.
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Amoeboid, rod-like and clustered (in association with protein deposits), were only present
in some rare examples.
Figure 6. Illustration of glial cells associated to protein deposits by astroglial (GFAP antibody;
arrowhead) and microglial (CD68 and MHCII antibodies; arrowhead) immunostaining, respec-
tively. (A) Astrocytic process associated with Kuru plaque (arrow) in granular layer of cerebellum.
(B) Microglial process associated to protein aggregation or clustered morphology associated with
protein deposit (arrow; magnification: 40×).
Figure 7. Reactive microglial morphology found in CJD cerebella (CD68 and MHCII antibodies). (A) Dystrophic. (B) Rod-like.
(C) Amoeboid. (D) Hypertrophic (E) Ramified. Furthermore, those also found in the frontal cortex (F) Dystrophic. (G) Rod-
like. (H) Amoeboid.
2.3.2. Ultrastructural Findings
Samples showed well-preserved membranes, mitochondria crests, and homogeneous
content in the matrix; however, because they came from tissue banks, they showed a much
poorer preservation of their ultrastructure in comparison with cases that are fixed with
aldehydes. Moreover, it is well recognized that the spongiotic changes associated with the
CJD neurodegenerative process result in tissue damage of the sort seen in the micrographs
shown here. This makes it harder to distinguish pathologic lesions from fixation artifacts at
the sub-cellular level.
Nevertheless, all CJD samples allowed observing distinctive ultrastructural pathologi-
cal changes of prion disease in relation with intermediate gliofilaments. This cytoskeletal
structural filament, as the most characteristic component in astrocytes, was found located
in close association with lesions such as vacuolation and alterations of myelin (Figure 8).
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Figure 8. An evident increase of astroglial filaments was found to be associated with two essential neuropathological
lesions in prion diseases. (A) Alteration of myelin (arrow) and (B) vacuolation (*, membrane disruption and curled
fragments inside).
3. Discussion
The hallmark neuropathological features of prion diseases are spongiosis, neuronal
loss, misfolding prion protein deposits, and gliosis. Traditionally, pathological prion
protein accumulation and its relation to neuronal death have dominated prion research,
despite gliosis being a prominent feature in prion-affected brains. Consequently, the
immunological function of glial cells had been a neglected aspect of research in this group
of diseases.
Nevertheless, in recent years, the neuroinflammatory hypothesis has suggested that
the host immune system is profoundly involved in neurodegeneration, playing an ac-
celerating or even causative role in this process [9,12,41]. Inflammation implicates the
modulation of immunological molecules (cytokines and interleukins), blood brain bar-
rier (BBB) breakdown, and leukocyte infiltration. This last characteristic is not found in
prion diseases nor other neurodegenerative diseases and constitutes a major difference
from the classic inflammation found in other brain pathologies, such as those caused
by infectious pathogens.
The present study focused on reactive astroglia and microglia as the major glial cells
involved in the immune response and, consequently, in the process of neuroinflammation.
We chose to examine the cerebellum, as one of the most affected encephalic areas, and the
frontal cortex, as a brain region where prion propagation is sometimes less pronounced in
certain CJD types. Furthermore, it is relevant to point out that biopsy and autopsy samples
from both of these brain regions are commonly used in the diagnosis of clinical CJD cases.
An exhaustive study has recently been published seeking to establish whether different
glial profiles support molecular and histopathological typing for prion strain characteriza-
tion [37]. In contrast, the study presented here represents an attempt to establish, for the
first time, what specific variations of neuroglia activation form a common denominator
found for all prion types.
This and other previous published quantitative studies have demonstrated a pro-
nounced heterogeneity of glial distribution and intensity among different CJD types,
probably in accordance with the individual host immune system participation. Perhaps it
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is also because, as known, neuroinflammation is not homogeneous, affecting cerebral areas
differentially, and that is why glial cells, although being defined as a fundamental part of
the process, do not behave uniformly in all cases. If a lineal process is involved, then case-
to-case and regional differences may represent different stages in the neuroinflammation
process. Several actors would take part in this event of neuroinflammation. The close corre-
lation between astrogliosis and microgliosis demonstrated in this study would support this
hypothesis, indicating that a combination of both glial types underlie neuroinflammation
by mediating, exacerbating or failing to prevent the toxic effects of protein accumulation
in the brain. Additionally, the close correlation of glial hyperplasia/hypertrophy and
spongiosis in prion disease, as confirmed by ultrastructural examination in this and our
previous studies on animal [42,43] as well as human prion [38] affected brains, strongly
supports the essential role of neuroglia in the neurodegenerative process. Taken together,
it would support a potential cooperative action between astrocytes and microglia in the
final neuronal damage, as previously suggested by some other authors [27].
The microglial role in prion disease remains controversial. It has been established
previously that there is a strong relationship between widespread deposition of PrPsc
and microgliosis in different experimental models [5,13,44,45]. However, in spite of the
association between microgliosis and PrPsc deposits in sCJD subtypes, some exceptions
are also found, such as the MMT2 subtype [37]. Moreover, specific brain regions where
PrPsc has been detected by highly sensitive assays such as RT-QuIC did not show reactive
microglia [46], supporting our statistical results questioning the association between mi-
crogliosis and widespread PrPsc deposition depending on CJD types. Although at first
glance the results presented here might appear conflicting, since microglia intensity and
extension were assessed layer by layer in two specific brain areas (cerebellum and frontal
cortex), we also focused on the whole CJD spectrum (genetic, sporadic, and acquired), and
these studies provide reliable and novel complementary conclusions for contributing to
the knowledge of the real microglial lead in CJD progression.
This lack of correlation between PrPsc deposits and microglial profiles is consistent
with the idea that not only misfolded protein deposit causes neurodegeneration. It is in
conflict with the hypothesis that PrPsc alone is toxic to neurons, without any involvement
requirement of these historically supporting cells. Some authors also found no association
between spongiosis and PrPsc deposition in CJD tissues [47,48]. This along with the fact
that gliosis is related to vacuolation confirms that other pathological events could occur
in prion disease. A much more complex series of process may be involved including
glial cells as main characters in the neuroinflammatory process [15]; or perhaps playing a
neuroprotective role at least during the early stages [29,49].
Previous morphological studies of astroglial changes [38,39] constituted a useful
tool for investigating prion pathogenesis by seeking evidence of common profiles shared
by all studied CJD cases. The present study confirms that there are common features
regardless of prion types. Several studies had been focused on the involvement of this
cellular type in prion diseases by using cell cultures or experimental animal models;
however, their real role is still unknown perhaps in part because of scarce studies focused
on how they act in vivo [50]. Astrogliosis, known as hypertrophy and/or hyperplasia of
astrocytes, is commonly observed along with the increase of neuropathological findings,
although unaffected brain areas occasionally show high astrogliosis too [4]. It is known that
astrocytes are the first cells that show PrPsc deposits in prion disease progression [2], with it
being possible to infect mice whose own PrPc is exclusively expressed in astrocytes, besides
research studies pointing out close relationship between infection susceptibility and PRNP
genotype of iPSC-derived astrocytes [8]. Only few of them deal with the different CJD
types and none in relation to the glial alterations common for all of them.
In biology, a key idea is that structure determines function. Therefore, a profound
alteration of morphology in glial cells implies major changes to cellular function and
physiology [51,52]. In Alzheimer´s disease, astrogliosis seems to refer to morphological
glial changes instead of cell proliferation [53]. These, along with our findings described
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here, support the significance of this contribution to the knowledge about glial changes in
order to approach pathogenesis of neurodegenerative diseases.
It is widely known that the pleomorphic properties of microglial cells, as well as the
presence of typical microglia morphologies, are associated with health and disease. The
traditional term ‘resting’ microglia (i.e., ‘not activated’ microglia) may be misleading [18]
because these cells elaborate many fine processes forming glial networks that regulate
physiological events [54]. Referring to amoeboid or hypertrophic microglia, these reflect
activation that indicates functional changes in response to pathological conditions [16]
Some other phenotypic changes such as dystrophic changes could affect tissue homeostasis.
Currently, the precise meaning of each of all these phenotypic changes constitutes a real
challenge to neuropathology [18].
Specifically, in this study about prion diseases, a total of five morphologies have
been reported. First, amoeboid morphology as a macrophage-like morphology related to
enhancing activation and phagocytosis [17]; ramified, characterized by many fine processes,
in spite of being named ‘resting microglia’ because it is present in healthy state, was also
present in pathological events; and hypertrophic, showing thickened soma and shortened
cellular prolongations, which could represent an intermediate state of ramified microglia
in activation gradient [55].
Morphology known as rod cells or rod-like has been also detected in this study as
markedly elongated, with scanty cytoplasm, and in a few processes [17]. Their function
is largely unknown, but it is speculated that it could indicate a protective role [56,57].
Typically associated with chronic diseases such as neurosyphilis, subacute sclerosing
panencephalitis, brain injury, and neurological diseases [55,57], rod cells are also present in
neurodegenerative disease and aging [55]. As described here, this could be explained as
senescent morphology since most patients develop CJD in old age. However, this question
still remains unclear.
The last morphology found here, dystrophic morphology, characteristic of aging, is
recognized as senescent and is occasionally detected in AD cases (with mild neuroinflam-
mation). This is the first time it has been reported in prion diseases. Although the concept
of ‘diseased microglia’ is raised in CJD [18,58], this kind of microglia was characterized
as having an atypical morphology, showing intracytoplasmic vacuolation, spheroid frag-
mented cytoplasmic processes, and loss of distal branches. It has also been associated with
cellular malfunction, lost homeostasis surveillance, and final neurodegeneration [59,60].
The frequent presence of this dystrophic microglial morphology would suggest a potential
neurotoxic role for this cell in a neuroinflammatory context, in contrast to a neuroprotective
role. This could be due to: (1) Microglial cells potentially reacting to specific misfolded
protein (PrPsc) and inducing morphological changes along with hyperplasia cellular that
finally imply detrimental effect, or (2) the presence of this dystrophic microglia could
involve a loss of tissue homeostasis in addition to cellular function.
On the whole, all these morphological changes could represent a continuum patho-
logical event between minimally to maximally activated microglia, including many grada-
tions [16,18].
Regarding astroglial morphology, the morphological change between radial and
varicose in the molecular layer of cerebellum had been reported in our previous studies re-
garding the natural Scrapie model [61], gCJD and sCJD [38], and prion-like diseases [39,40].
Nevertheless, these results have been observed here for first time irrespective of prion type,
as it was found in all CJD subtypes, including VPSPr.
Perhaps the most outstanding finding highlighted here is those morphological changes
in interlaminar astroglia detected in the frontal lobe for first time in all CJD types. This
cellular type is an astroglial population exclusively located in the frontal cortex of non-
human primates [62] and humans [63] whose role remains unknown. In the healthy state,
it forms palisade or cable-like structures that cover layers one to four of the cerebral
cortex. Neurological diseases such as Alzheimer’s disease [64], Down syndrome [65], and
psychological disorders such as bipolar disorder [66] have been reported to show alterations
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in this peculiar glial form. The results provided here about the novel morphological changes
concerning this specific astroglia in prion diseases are in agreement with those described
for Alzheimer’s disease. The variations shown in bipolar disorder are less pronounced,
and only messy or shortening of this cellular type was shown. Thus, this morphological
alteration has been associated with neurological signs. Maybe the prodromal phase of
prion diseases including neurological symptoms [67] could be reflecting these astroglial
changes, as pointed out by other authors [68].
The main pathological changes that have been characterized in this peculiar astroglia
include palisade disorganization, even breakdown, and the dramatic presence of thicker
terminal masses. In those cases where the breakdown of the characteristic palisade of this
astroglial type is evidenced, this neuropathological change might be triggered by alteration
of the homeostasis associated with prion protein presence. Disruption, or even absence,
described in this peculiar astroglial type, might also concur with subsequent images of a
continuous process. The presence of thicker terminal masses observed in some CJD cases
here had been detected in aged or adult [63] as well as in Alzheimer’s disease affected
cases [64]. Despite the physiological changes occurring in these cells still remain unknown,
its explanation seems to consist of constituting a structure where a re-emplacement of
intermediate filaments occurs. Similarly, varicose astroglia observed in cerebella show a
morphology that could resemble NG2 cells. NG2 represents an oligodendroglial progenitor
marker, even considered to be the fourth glial type with astroglia, microglia, and oligoden-
droglia [69]. The hypothesis that astrocytes alter their morphology until they are replaced
by these progenitor cells in an attempt to repair brain damage by compensating neuronal
loss should be investigated.
As cited, microglia show two pathological responses: (1) Graded morphological
changes representing an increase in their physiological activity as a consequence of the neu-
rodegenerative process and (2) morphological alterations, such as dystrophic or rod-like,
of specific microglial populations that maybe show cellular injury as tisular homeostasis
due to an indirect effect of the neurodegenerative process. In the same way as microglia,
two alternative justifications could be proposed for astrocytic alterations: (1) Hypertro-
phy and/or hyperplasia of astrocytes as response to damage, defined as astrogliosis and
(2) affectation of tissue homeostasis in specific astrocytic population, as interlaminar glia,
caused by brain damage.
4. Materials and Methods
4.1. Samples
All tissue samples were kindly provided by the MRC Edinburgh Brain & Tissue bank
(Edinburgh, UK - Brain Bank 16-ES-0084). Samples included 21 cases with a neuropatho-
logically confirmed diagnosis of human prion disease and consisted of cases affected by
different subtypes of CJD (sCJD, vCJD, gCJD, iCJD) and VPSPr. Where available, differ-
ent PRNP codon 129 genotypes were included in the cases selected. Three additional
non-dementia cases were included as controls (Table 2).
Formalin-fixed tissue samples of 3–5 mm, corresponding to sagittal cerebellar (in-
cluding granular, Purkinje cell and molecular layers, and white matter) and frontal cortex
(including I to VI layers and white matter) samples, were investigated in the study. In
Biosafety Level-3 (BSL3) facilities, tissue samples were treated by immersion in formic acid
for 1 h for prion inactivation before processing to paraffin embedded-tissue blocks.
Five micrometer tissue sections from all samples were sectioned for hematoxylin and
eosin staining (H/E) and immunostaining with several antibodies following previously
described protocols [38].
Research protocols applied on these samples were approved by the Ethical Commit-
tee for Clinical Research from Government of Aragón (CEICA; REFERENCE NUMBER:
PI 15/0036, Acta Nº 05/2015).
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Table 2. Data provided by respective Brain Bank corresponding to patients affected by each CJD type.
Patient Aetiology Gender Age Genetic Data PrP Isotype
1 Sporadic M 70 MM nil 2
2 Sporadic M 70 MM nil 2
3 Sporadic F 78 MM nil 1
4 Sporadic M 71 MV nil 2
5 Sporadic F 63 MV nil 2
6 Sporadic F 71 MV nil 2
7 Sporadic M 74 VV nil 2
8 Sporadic F 73 VV nil 2
9 Sporadic F 77 VV nil 2
10 Familial F 56 MM E200K na
11 Familial M 78 MV E200K na
12 Familial F 53 MM E200K na
13 Iatrogenic (GHT) M 42 MM nil 1
14 Iatrogenic (GHT) F 34 MV nil 1 + 2
15 Iatrogenic (DURA) F 27 MM nil 1
16 Variant M 59 MM nil 2B
17 Variant M 62 MM nil 2B
18 Variant F 32 MM nil 2B
19 VPSPr M 66 VV
20 VPSPr F 76 VV lMWt
21 VPSPr M 66 MV
22 Control F 69
23 Control M 63
24 Control M 74
PrP, prion protein; na, not available data; MM, MV, VV (M, methionine; V, valine): genotypes at codon 129 of PrP
gene; Mutations are indicated when PrP gene mutation present; Nil, when no present.
4.2. GFAP Immunolabelling
Briefly, tissue sections were deparaffinized and rehydrated prior to endogenous per-
oxidase inactivation by incubation of all sections with peroxidase blocking reagent (5 min;
DAKO, Glostrup, Denmark). Sections were incubated with a primary antibody against glial
fibrillary acidic protein (GFAP, 1/500 for 30 min RT; DAKO), followed by an incubation
with enzyme-conjugated polymer EnvisionTM (30 min, RT; DAKO). DAB PLUS (10 min)
was used to visualize staining before sections were counter-stained with hematoxylin.
4.3. Reactive Microglia Detection
The protocol used for reactive microglia labelling was as that described for GFAP,
with the exception of primary antibody. In this case, CD68 (1/500, 30 min RT; DAKO) and
MHCII (1/200, 30 min RT; DAKO) were used.
4.4. PrPsc Detection
PrPsc immunodetection requires an epitope unmasking protocol consisting of immer-
sion in 96% formic acid (5 min), digestion with proteinase K (5 min, RT; Roche, Reinach,
Switzerland) and autoclaving in distilled water at 121 ◦C (10 min). After incubation with
the prion protein antibody (12F10 at 1/1700 dilution; SPI Bio, Darmstadt, Germany) for
1 h RT, immunostaining was completed using the EnVision™ mouse polymer (DAKO,
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Glostrup, Denmark) kit. Following the previously described scoring system [38], all im-
munolabelled sections were thoroughly assessed in each layer regarding morphology,
intensity, and distribution variations.
A semi quantitative scoring system was used in accordance with that described in
Monzón et al. [38], in which scores were from negative (−) to a maximum (++++) according
to the density and the extension of the labeling deposits. Spongiosis was also subjectively
scored according to the number of vacuoles, from absence (−) to very high density (++++).
Furthermore, immunostaining morphology for each marker was classified in accordance
with the previously described patterns. For PrPsc this included: Linear, granular, spot,
coalescent or plaques, pericellular, patchy, perivacuolar, perivascular, plaque-like, plaque
(kuru, unicentric, multicentric, florid plaque, microplaques), coarse, or synaptic; for GFAP:
Severe diffuse, moderate, perineuronal, or radial [20] and for reactive microglia: Ramified,
amoeboid, dystrophic, or rod-like.
4.5. Statistical Analysis
Rating data were entered into an Excel spreadsheet and analyzed by Servicio de Apoyo
Metodológico y Estadístico (SAME)–IACS, University of Zaragoza.
With the aim of testing for normality of the distribution, the Kolmogorov Smirnov
test was conducted. Kruskal–Wallis test was performed for analysis. As significant dif-
ferences between the groups were detected, the Mann Whitney U test post hoc testing
(Bonferroni correction) was performed to identify the groups between which significant
differences existed.
The correlation between all the variables analyzed was measured by Pearson’s correlation.
P values < 0.05 were considered statistically significant.
4.6. Electron Microscopy Studies
With the aim of visualizing potential morphological alterations between the different
CJD types, an ultrastructural study was performed. Post-fixation with glutaraldehyde
2.5% and 2% osmium before embedding in araldite (Durcupan, Fluka AG, Buchs SG,
Switzerland) was followed in all cases. Ultrathin (0.08 µm) sections were cut from 1%
toluidine blue-stained semi-thin sections (1.5 µm), collected on Formvar-coated single-slot
grids and counterstained with 1% uranyl acetate and Reynold’s lead citrate for 10 min.
Samples were examined under FEI Tecnai G2 Spirit (60,000 KV).
5. Conclusions
In conclusion, the results provided here point to the fact that astroglial and microglial
intensity and extension are independent of their morphological changes. Consequently,
the relevance of studies about morphological changes, usually undervalued, should be
confirmed as indisputable in order to understand the neuropathological events related to
glial behavior. The cellular phenotype truly reveals specific cellular function.
Although most authors presenting morphological alterations have intended to use
their differences in order to classify and sub-classify specific neurodegenerative disease, we
believe that focusing on common features contributes to our understanding of neuropatho-
logical process based on the newly emerging neuroinflammatory hypothesis.
The increase of both glial cell types (astroglia/microglia) and the relationship with the
increase in histopathological lesions suggest a potential neurotoxicity of glial cells in prion
diseases, as described by Liddlelow et al. [27]. To determine whether astrocytes driven
by ‘activated’ microglia or astrocyte dysfunction are the actual responsible actors for this
neurotoxicity, urgent study is required.
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